Investigación / Grupos de investigación

Grupo  2

Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Publicaciones (884)

  • Radosa, JC; Cobo, SLT; Dzieran, J; Glastetter, E; Chen, C; Lingohr-Smith, M; Pasupuleti, V; Brufsky, A.

    Palbociclib treatment in patients with HR+/HER2-advanced or metastatic breast cancer and visceral metastasis: A systematic literature review

    BREAST. 2025; 84: [doi:10.1016/j.breast.2025.104569]

  • de la Peña, FA; Novoa, SA; Gregori, JG; Cortijo, LG; Carrasco, FH; Martínez, MTM; Estévez, CM; Stradella, A; Losada, MJV; Ciruelos, E.

    SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; 28(1): 105-125 [doi:10.1007/s12094-025-04139-x]

  • Espinosa, E; Berciano-Guerrero, MA; Muñoz-Couselo, E; Puértolas, T; Manzano, JL; Soria, A; De Miguel, PA; Crespo, G; Sanz, LG; Cerezuela-Fuentes, P; de la Rosa, CA; Majem, M; Castaño, AG; Berrocal, A; Arroyo, FRG; de la Borbolla, MR; Bellido, L; Martínez, JM; Fernández, LA; Carnicero, AM; Castro, RL; Rodríguez, AB; Lecumberri, MJ; Guzmán, JCV; Balea, BC; Rodríguez, JF; Bautista, JV; Pérez, VN; Mujika, K; Subias, MC; Hernández, B; Algarra, SM; Márquez-Rodas, I.

    Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04098-3]

  • Salgado, M; de la Camara-Gomez, J; García-Escobar, I; Alvarez-Llosa, RC; González-Villarroel, P; Garay, DF; Pàmpols-Felip, M; Guillot-Morales, M; Pelegrín-Mateo, FJ; Jimenez-Orozco, E; Sastre, J; De Castro, EM; Coma, E; Bouzas, LP; Ferrer-Pérez, AI; Mompradé-Olivé, E; Cousillas-Castiñeiras, A; Covela-Rúa, M; Rojas, M; Querol, R; Díaz, LR; Merino, M; Gil, M; Sánchez-Cánovas, M; Elías, T; Marrupe-González, D; Sánchez-Gil, B; Carmona-Campos, M; García-Ferron, M; Soria, JM; Muñoz, A.

    Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design

    BMC CANCER. 2025; 25(1): [doi:10.1186/s12885-025-14620-z]

  • Verrill, M; Lux, MP; Gligorov, J; Geisler, J; Duchnowska, R; Elsberger, B; Martin, M.

    Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges

    Future Oncology. 2025; 21(27): 3573-3583 Nº de citas: 1 [doi:10.1080/14796694.2025.2577335]

  • Masini, S; Basa, MA; Calles, A; Cabellos, RA; Echebarria, ID; Puchol, CT; Kareaga, MM; Cabezon-Gutierrez, L; Perez, MCE; Lage, Y; Lorenzo, EG; Navarro, F; Sereno, M; Martínez, SF; García-Benito, C; Pinto, LM; Andrade, CA; Sequero, S; Martinez, JM; Lopez-Martín, A; Martínez, AA; Martín-Soberon, MC; Lucia-Gozalvez, C; Rubio, J; Tallafigo, L; Garrido, A; Peressini, M; Torres-Jimenez, J; Zurera, M; Bote, H; Ponce, S; Paz-Ares, L; Zugazagoitia, J; Baena, J.

    Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression = 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)

    Cancers. 2025; 17(22): [doi:10.3390/cancers17223643]

  • Garcia-Saenz, JA; Lopez-Barajas, IB; Echavarria, I; Gonzalez, CH; Vila, MM; Antón, FM; Pernas, S; Cajal, TRY; Ribelles, N; Ezquerra, MB.

    SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; 28(1): 126-147 Nº de citas: 1 [doi:10.1007/s12094-025-04102-w]

  • Smith, M; Piulats, J; Todenhöfer, T; Lee, JL; Arija, JA; Mazilu, L; Azad, A; Alonso-Gordoa, T; McGovern, U; Choudhury, A; Horvath, L; Ye, DW; Han, WQ; Suzuki, H; Uemura, H; Mckay, R; Ades, S; Fléchon, A; Pieczonka, C; Fernandes, MS; Hulstijn, M; Lithio, A; Nacerddine, K; Agarwal, N.

    Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

    LANCET ONCOLOGY. 2025; 26(11): 1489-1500 Nº de citas: 3

  • Crown, J; Stroyakovskii, D; Huang, CS; Yardley, DA; Fasching, PA; Bardia, A; Chia, S; Im, SA; Martin, M; Xu, B; Barrios, CH; Untch, M; Moroose, R; Hurvitz, SA; Hortobagyi, GN; Slamon, DJ; Visco, F; Spera, G; Zarate, JP; Halligan, D; Li, Z; Loi, S.

    Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year followup of NATALEE efficacy outcomes and updated overall survival

    Esmo Open. 2025; 10(11): Nº de citas: 8 [doi:10.1016/j.esmoop.2025.105858]

  • Lala, M; Bardia, A; Calles, A; Danesi, R; Freshwater, T; Healy, JA; Herbst, RS.

    Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis

    TARGETED ONCOLOGY. 2025; 20(6): 955-965 [doi:10.1007/s11523-025-01185-x]

  • Castet, F; Fabregat-Franco, C; Bridgewater, J; Kim, JW; Rimini, M; La Casta, A; Lamarca, A; Kang, MS; Salani, F; Castillo, A; Lopes, A; Hyung, J; Rimassa, L; Adeva, J; López-Valbuena, D; Basagaña-Farres, M; Vaja, S; Mak, KM; Tian, TV; Muñoz, A; Casadei-Gardini, A; DURVABTC Grp; Yoo, C; Valle, JW; Macarulla, T.

    Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer

    JOURNAL OF HEPATOLOGY. 2025; 83(5): Nº de citas: 1 [doi:10.1016/j.jhep.2025.05.020]

  • Rosa, AA; Carolina, AP; Marta, AV; Francisco, A; Adriana, FG; Natalia, G; Pablo, LL; Cristina, MF; Lidia, MS; Ulrike, N; Marina, S; Guillermo, HT; Henar, CG; Ana, GOD.

    Desmoid Tumors-Experience from a Referral Center, Part 1: Multidisciplinary Review and Practical Recommendations

    Cancers. 2025; 17(21): Nº de citas: 1 [doi:10.3390/cancers17213470]

  • Lopez, BH; Montealegre, MC; Soulas, C; Rufrancos, BA; Cuéllar, MLGO; Millán, MD; Lopez, LV; Cobo, SLT; Gilarranz, YJ; Díaz-Guardamino, IE; Jara, P; Jiménez, MM; Sánchez, TM; Beltrán, MJM; Montero, JCD; Barrio, SC.

    Randomized pilot study of an individualized multimodal exercise, nutrition, and behavior intervention in breast cancer patients treated with ovarian function suppression: protocol proposal for The OvS Breast ENBI Project

    Frontiers in Oncology. 2025; 15: Nº de citas: 1 [doi:10.3389/fonc.2025.1622622]

  • Caraballo, IG; Delgado, BL; Zamorano, MR; Salgado, M; Pachón, V; Galán, JM; Castellón, V; Gardeazabal, I; Ferrer, A; Pérez, JR; Escobar, IG; Fernández, I; Quintanar, T; Font, C; Alsar, JS; Morán, LO; Fernández, JMS; Martín, AJM.

    Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis

    CLINICAL & TRANSLATIONAL ONCOLOGY. 2025; : [doi:10.1007/s12094-025-04099-2]

  • Pacheco-Barcia, V; Mariño-Mendez, A; Hernandez-Jimenez, E; Jimenez-Fonseca, P; Martín, AJM; Custodio-Cabello, S; Palka-Kotlowska, M; Gonzalez-Diaz, I; Cabezon-Gutierrez, L.

    Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives

    World Journal of Clinical Oncology. 2025; 16(10): [doi:10.5306/wjco.v16.i10.107877]

  • Ascierto, PA; Del Vecchio, M; Merelli, B; Gogas, H; Arance, AM; Dalle, S; Cowey, CL; Schenker, M; Gaudy-Marqueste, C; Pigozzo, J; Márquez-Rodas, I; Butler, MO; Di Giacomo, AM; Gligich, O; de la Cruz-merino, L; Arenberger, P; Atkinson, V; Nathan, P; Hill, A; Millward, M; Fecher, LA; Khushalani, NI; Queirolo, P; Soomro, R; Rathod, D; Askelson, M; Benito, MP; Joseph, D; Larkin, J.

    Nivolumab for Resected Stage III or IV Melanoma at 9 Years

    NEW ENGLAND JOURNAL OF MEDICINE. 2025; 394(4): Nº de citas: 8 [doi:10.1056/NEJMoa2504966]

  • Li, J; Deng, T; Gu, YH; Blanco, AC; Li, ZH; Bai, CM; Wu, L; Huang, J; Li, XY; Yao, Y; Song, ZB; Li, YS; Liu, L; Xing, LG; Wu, WM; Martinez-Perez, J; Hubert, A; Zugazagoitia, J; Zhang, J; Wang, YS; Zhao, YQ; Wen, GL; Xia, GH; Zhong, DS; Chen, XQ; Jiang, KR; Wang-Gillam, A; Ding, YL; Liu, SM; Rao, ZY; Liu, XH; Shen, L.

    Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

    Cancer Communications. 2025; : [doi:10.1002/cac2.70056]

  • González-del-Alba, A; Ballesteros, CM; Arranz, JA; Gallardo, E; Sarrió, RG; Campos, FL; Muñoz-Rodríguez, J; Méndez-Vidal, MJ; de Iturriaga, AG.

    Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

    Cancers. 2025; 17(19): Nº de citas: 1 [doi:10.3390/cancers17193208]